Regenicin Company Executives
| RGIN Stock | USD 0.0003 0.00 0.00% |
Regenicin employs about 3 people. The company is managed by 3 executives with a total tenure of roughly 46 years, averaging almost 15.0 years of service per executive, having 1.0 employees per reported executive. Analysis of Regenicin's management performance can provide insight into the firm performance.
| Randall McCoy Chairman Chairman, CEO and Pres |
Regenicin |
Regenicin Management Team Effectiveness
The company has return on total asset (ROA) of (37.3831) % which means that it has lost $37.3831 on every $100 spent on assets. This is way below average. Regenicin's management efficiency ratios could be used to measure how well Regenicin manages its routine affairs as well as how well it operates its assets and liabilities.Regenicin owns a total of 153.48 Million outstanding shares. Regenicin holds 18.15 pct. of its outstanding shares held by insiders and 0.018 pct. owned by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in pink sheets such as Regenicin in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Regenicin, and when they decide to sell, the pink sheet will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Regenicin Workforce Comparison
Regenicin is rated below average in number of employees category among its peers. The total workforce of Biotechnology industry is at this time estimated at about 94.0. Regenicin holds roughly 3.0 in number of employees claiming about 3% of stocks in Biotechnology industry.
Regenicin Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Regenicin Price Series Summation is a cross summation of Regenicin price series and its benchmark/peer.
Regenicin Notable Stakeholders
A Regenicin stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Regenicin often face trade-offs trying to please all of them. Regenicin's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Regenicin's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Randall McCoy | Chairman, CEO and Pres | Profile | |
| John Weber | Interim CFO and Director | Profile | |
| Roy Nelson | Chief Science Officer | Profile |
About Regenicin Management Performance
The success or failure of an entity such as Regenicin often depends on how effective the management is. Regenicin management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Regenicin management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Regenicin management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. Regenicin, Inc. was incorporated in 2007 and is headquartered in Little Falls, New Jersey. Regenicin operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 3 people.
Regenicin Workforce Analysis
Traditionally, organizations such as Regenicin use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Regenicin within its industry.Regenicin Manpower Efficiency
Return on Regenicin Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 213.1K | |
| Net Loss Per Executive | 213.1K |
Other Information on Investing in Regenicin Pink Sheet
Regenicin financial ratios help investors to determine whether Regenicin Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Regenicin with respect to the benefits of owning Regenicin security.